Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Morgan M. Richey, Ph.D, MPH

Research Pharmacoepidemiologist
RTI International, United States

Bradley Layton, PhD, FISPE, is a Director of Epidemiology at RTI Health Solutions with vast experience leading studies using existing health care data to evaluate the use, safety, and effectiveness of pharmaceuticals, vaccines, and other medical products. He has considerable leadership experience in the design, conduct, analysis, and reporting of epidemiologic studies and has over 12 years of experience in the field of pharmacoepidemiology. His experience and publications span a wide range of substantive areas, including renal, cardiovascular, men’s health, vaccines, rare diseases, and pregnancy, and incorporate multidatabase and multinational studies. He has been a project leader or scientific contributor within international consortia of researchers, including the FDA BEST Initiative and Vac4EU. Dr. Layton also has experience with epidemiologic methods, lecturing to clinical and public health audiences about observational study design, large database utilization, and propensity score analysis.

Dr. Layton received his master's and doctorate degrees in epidemiology from the Department of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, focusing in pharmacoepidemiology with an emphasis in renal disease. Prior to joining RTI-HS, he was a member of the faculty in the Pharmacoepidemiology Program in the University of North Carolina Department of Epidemiology, and he is currently an adjunct associate professor at the University of North Carolina. Dr. Layton is a fellow and an active member of the International Society of Pharmacoepidemiology, having served on the Scientific Program Committee as the chair of the spotlight poster sessions, on the Public Policy Committee, and as the Chair of the Vaccine Special Interest Group.

Disclosure information not submitted.

Presentation(s):